Advanced Biomed Inc. (ADVB)

Overview

Advanced Biomed Inc. is an investment holding company specializing in the research and development of innovative microfluidic biochip technologies. Based in New York, the company focuses on providing precision oncology solutions for detection, diagnosis, and treatment of cancer patients in Taiwan. Since its establishment in 2014, Advanced Biomed has been dedicated to advancing medical technologies that enhance the capabilities of clinicians in managing cancer. The company also operates medical clinics in the People's Republic of China, further expanding its reach and contributions to the healthcare sector.

Products and Services

• A+Pre:

  This fully automated sample preparation system is designed to pre-concentrate diluted blood samples, streamlining the process for clinical testing and improving accuracy in results.

• AC-1000:

  A specialized rare cell device that addresses the challenges in detecting hypercoagulable state samples in tumor patients, making it an essential tool in precision oncology.

• A+SCDrop:

  A device focused on capturing circulating tumor cells (CTCs) at the single-cell level, enhancing the ability to monitor and analyze cancer progression and treatment response.

• A+CellScan:

  An analyzer equipped with an immunostaining chip designed for the immunostaining and analysis of samples processed by the AC-1000, aiding in the evaluation of cancer cells and their characteristics.

• A+CTCE Kit:

  This immunochromogenic kit identifies epithelial circulating tumor cells using the immunochromogenicity of specific antibodies, playing a crucial role in monitoring cancer markers.

• A+CTCM Kit:

  Developed to recognize mesenchymal circulating tumor cells, this kit utilizes antibodies to detect specific cell characteristics, facilitating cancer diagnostics and research.

• A+EMT:

  This kit is used for identifying epithelial-to-mesenchymal circulating tumor cells, which are crucial in understanding tumor metastasis and therapeutic resistance.

• A+CM:

  Focusing on tumor-associated macrophages, this kit identifies these cells based on their immunochromogenicity, providing important insights into the tumor microenvironment.

• A+LCGuard:

  In development for early screening of lung cancer, this innovative product aims to enhance early detection rates and improve patient outcomes through timely intervention.